Pfizer gets full US FDA nod for LORBRENA as first-line treatment for ALK-Positive metastatic NSCLC
Approval is based on CROWN trial, which showed a 72 per cent reduction in risk of progression or death for treatment with LORBRENA…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.